STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Zoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment Increase

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
dividends

PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on Tuesday, March 3, 2026, to all holders of record of the Company’s common stock as of the close of business on Tuesday, January 20, 2026.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock producers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $9.3 billion in 2024 with approximately 13,800 employees. For more information, visit www.zoetis.com.

DISCLOSURE NOTICES

Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.

These forward-looking statements include, but are not limited to, statements which reflect the current views of Zoetis with respect to business plans or prospects, future operating or financial performance, future use of cash and dividend payments, and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.

ZTS-COR
ZTS-IR
ZTS-FIN

Media Contacts:

Jennifer Albano

1-862-399-0810 (o)

jennifer.albano@zoetis.com



Laura Panza

1-973-975-5176 (o)

laura.panza@zoetis.com



Investor Contacts:

Steve Frank

1-973-822-7141 (o)

steve.frank@zoetis.com



Nick Soonthornchai

1-973-443-2792 (o)

nick.soonthornchai@zoetis.com

Source: Zoetis Inc.

Zoetis Inc

NYSE:ZTS

ZTS Rankings

ZTS Latest News

ZTS Latest SEC Filings

ZTS Stock Data

51.01B
440.24M
0.09%
98.66%
1.75%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
PARSIPPANY